The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OMCL | -23.45% | -62.96% | -18.01% | +218% |
| S&P | +15.06% | +95.03% | +14.29% | +459% |
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.
The healthcare medication management company released lowered guidance.
These companies have a history of creating shareholder value -- and still have plenty of room for growth.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $290.56M | 5.0% |
| Gross Profit | $127.68M | 11.7% |
| Gross Margin | 43.94% | 2.6% |
| Market Cap | $1.38B | 10.8% |
| Market Cap / Employee | $0.38M | 0.0% |
| Employees | 3.6K | 0.0% |
| Net Income | $5.64M | 51.0% |
| EBITDA | $29.77M | 14.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $431.50M | -25.4% |
| Accounts Receivable | $232.68M | -3.5% |
| Inventory | 105.8 | 13.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $197.75M | -67.3% |
| Short Term Debt | $186.66M | 1683.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.04% | 2.0% |
| Return On Invested Capital | 1.76% | -1.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $30.97M | -37.0% |
| Operating Free Cash Flow | $42.76M | -27.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 169.73 | 76.94 | 59.60 | - | |
| Price to Book | 1.64 | 1.67 | 1.30 | 1.10 | 4.74% |
| Price to Sales | 1.90 | 1.88 | 1.43 | 1.20 | 4.19% |
| Price to Tangible Book Value | 8.39 | 8.57 | 6.19 | 4.90 | -27.24% |
| Price to Free Cash Flow TTM | 15.18 | 13.79 | 13.03 | 12.93 | 72.09% |
| Enterprise Value to EBITDA | 71.17 | 57.53 | 156.57 | 44.83 | -9.07% |
| Free Cash Flow Yield | 6.6% | 7.3% | 7.7% | 7.7% | -41.89% |
| Return on Equity | -1.5% | 1.0% | 1.7% | 1.9% | -206.69% |
| Total Debt | $614.14M | $382.55M | $385.83M | $384.41M | -37.54% |
OMCL earnings call for the period ending November 2, 2021.
OMCL earnings call for the period ending June 30, 2021.
OMCL earnings call for the period ending March 31, 2021.
OMCL earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
